GLP-1 Medications and Gallbladder Disease: What the STEP, SURMOUNT, and FDA Label Data Actually Show

GLP-1 medications do increase the rate of gallbladder problems — cholelithiasis, cholecystitis, and the surgical removal that sometimes follows — at a rate higher than placebo. The number is smaller than internet rumor suggests, but it is real, and it is written verbatim into the “Acute Gallbladder Disease” section of every FDA-approved GLP-1 label [5, 6, 7, 8, 9]. The 2022 He et al meta-analysis of 76 randomized trials and 103,371 patients (PMID 35344001) pooled the relative risk at 1.37 (95% CI 1.23-1.52) — about 27 additional biliary events per 10,000 person-years on a GLP-1 compared to placebo [4]. This piece walks through the actual per-drug percentages, the trial sources, the rapid-weight-loss confounder, and the cholecystitis symptoms you should not ignore.

The headline numbers, by drug

Every FDA-approved GLP-1 receptor agonist for either weight loss or type 2 diabetes lists acute gallbladder disease as a Warnings and Precautions section. The percentages below are pulled verbatim from the DailyMed-hosted prescribing information for each drug as of May 2026.

Two patterns stand out. First, the absolute event rates are small — under 3% even at the highest. Second, the gap between drug and placebo is largest where the weight loss is largest: Wegovy and Saxenda, both labeled for chronic weight management, show the widest spread; Zepbound shows a much smaller spread despite producing the most weight loss in head-to-head trials. The Saxenda label is the only one to explicitly state the risk “was greater” than weight loss alone would predict — pointing to a GLP-1-specific component on top of the rapid-loss mechanism. We will return to that distinction in the mechanism section.

What the trials report

The label percentages all trace back to the published phase-3 trials. The three most-cited:

• STEP 1 (Wilding et al, NEJM 2021, PMID 33567185) randomized 1,961 adults with overweight or obesity to once-weekly semaglutide 2.4 mg or placebo for 68 weeks. Gallbladder-related disorders, principally cholelithiasis, occurred in 2.6% of the semaglutide arm vs 1.2% of the placebo arm; serious hepatobiliary adverse events were reported in 1.3% vs 0.2% [1].
• STEP 2 (Davies et al, Lancet 2021, PMID 33667417) studied semaglutide 2.4 mg in adults with overweight or obesity and type 2 diabetes. Gallbladder-related symptoms occurred in 0.2% of the semaglutide arm vs 0.7% of placebo — counter-intuitively lower [2]. The likely explanation: T2D patients in STEP 2 lost less weight than the non-diabetic STEP 1 cohort, and slower weight loss reduces the gallstone-formation pressure that bariatric medicine has documented for decades.
• SURMOUNT-1 (Jastreboff et al, NEJM 2022, PMID 35658024) randomized 2,539 adults to tirzepatide 5/10/15 mg or placebo for 72 weeks. Cholelithiasis occurred in 1.1% of tirzepatide-treated patients vs 1.0% of placebo; cholecystitis in 0.7% vs 0.2%; cholecystectomy in 0.2% vs 0% [3]. The cholelithiasis numbers are statistically indistinguishable from placebo, even though tirzepatide patients lost >20% body weight.

The pattern across STEP and SURMOUNT is what most patient guides miss: cholelithiasis rates track with weight-loss magnitude and pace, not just with GLP-1 receptor agonism in the abstract. STEP 2's lower rate in slow-losing T2D patients and SURMOUNT-1's flat-vs-placebo rate in rapid-losing tirzepatide patients are not contradictions; they are evidence that the absolute risk is heavily modulated by how much, and how fast, a given patient loses weight on a given drug.

The big-picture meta-analysis

He et al's 2022 systematic review and meta-analysis, published in JAMA Internal Medicine (PMID 35344001), pooled 76 randomized trials enrolling 103,371 patients across diabetes, obesity, and other indications [4]. The headline findings:

• Overall biliary or gallbladder disease: relative risk 1.37 (95% CI 1.23-1.52).
• Cholelithiasis specifically: RR 1.27 (95% CI 1.10-1.47).
• Cholecystitis: RR 1.36 (95% CI 1.14-1.62).
• Cholecystectomy: RR 1.70 (95% CI 1.30-2.21).
• Absolute risk increase: roughly 27 additional cases per 10,000 person-years.

He et al stratified the pooled risk in two clinically important ways. First, by dose: trials of higher GLP-1 doses pooled at RR 1.56 (95% CI 1.36-1.78), while trials of lower doses pooled at RR 0.99 (95% CI 0.68-1.46) — not significantly elevated. Second, by treatment duration: longer trials (more than 26 weeks of exposure) pooled at RR 1.40, while shorter trials pooled at RR 0.79 (95% CI 0.55-1.13). Third, by indication: trials in obesity populations pooled substantially higher than trials in T2D populations [4]. All three stratifications point at the same underlying signal — more drug, longer exposure, and more weight loss all push the risk up — and they explain why a Wegovy patient, a Mounjaro patient, and a low-dose Ozempic patient face meaningfully different absolute risks.

Why GLP-1s do this — mechanism vs confounder

Two non-exclusive mechanisms are on the table. The first is well-established and is not specific to GLP-1s at all: any rapid weight loss above roughly 1.5 kg/week supersaturates bile with cholesterol and slows gallbladder emptying, so stones precipitate. The classic post-bariatric-surgery literature documents 30-71% incidence of new gallstones in the first six months without ursodeoxycholic acid (UDCA) prophylaxis (Sugerman 1995, PMID 11792152), and gallbladder ultrasound studies in commercial weight-loss programs show the same effect at lower magnitudes.

The second mechanism is GLP-1-specific: GLP-1 receptor activation slows gastric emptying and also appears to suppress postprandial gallbladder contraction, so bile sits in the gallbladder longer between meals. The Saxenda label is the clearest disclosure of this: it states the gallbladder risk in Saxenda-treated patients was elevated “even when accounting for weight loss differences” [7] — the only FDA GLP-1 label to put that distinction in writing.

Practically, both mechanisms reinforce each other in a fast responder: a Wegovy patient losing 15-20 kg in the first six months is exposed simultaneously to the rapid-loss cholesterol-saturation effect and the GLP-1-specific gallbladder-stasis effect. A slow responder on Ozempic 0.5 mg for type 2 diabetes faces only the second mechanism, weakly, which is consistent with the lower label rates for low-dose T2D semaglutide.

When to seek care

Acute cholecystitis is a medical emergency. The symptoms that the FDA labels and emergency-medicine references all point to:

• Sudden severe pain in the right upper abdomen, often starting an hour or two after a fatty meal, lasting more than 30 minutes.
• Pain radiating to the right shoulder or upper back.
• Fever, chills, or sweating that is out of proportion to the usual GLP-1 GI side effects.
• Nausea and vomiting that is more severe or more sustained than the GLP-1 baseline you have come to expect (see our GLP-1 nausea management guide for the typical pattern).
• Jaundice (yellowing of the skin or eyes), pale or clay-colored stools, dark urine — these suggest bile-duct obstruction and are higher-acuity.

Every FDA GLP-1 label tells the prescribing clinician that if cholecystitis is suspected, gallbladder studies and appropriate clinical follow-up are indicated [5, 6, 7, 8, 9]. From a patient's perspective, that translates to: do not wait it out, do not assume it is ordinary GLP-1 nausea, and do not try to self-manage with the antiemetic strategies that work for run-of-the-mill nausea. Acute cholecystitis can progress to gallbladder gangrene or perforation in 24-48 hours.

What this changes about the risk-benefit conversation

The point of cataloging the actual numbers is to make the risk-benefit conversation precise. Three observations matter:

1. Absolute risk is small but real. Roughly 27 additional gallbladder events per 10,000 person-years (compared to the >14% mean weight loss on semaglutide and >20% on tirzepatide) is a clinically reasonable trade for most adults pursuing significant weight loss. It is not zero, and it is not what some social-media commentary implies either.
2. Risk tracks with weight-loss magnitude and pace. Patients on the standard high-dose obesity regimens (Wegovy 2.4 mg, Zepbound 15 mg, Saxenda 3 mg) carry more risk than patients on low-dose T2D regimens. Patients losing >1.5 kg/week carry more risk than patients losing <0.5 kg/week. Slowing the titration, as discussed in our titration planner, reduces the rapid-loss component of the risk.
3. Pre-existing gallstones change the calculus. A patient with known asymptomatic cholelithiasis on ultrasound is at higher baseline risk of cholecystitis with any rapid weight loss. Discuss imaging history with your prescriber before starting; some clinicians order a baseline right-upper-quadrant ultrasound for higher-risk patients. Routine UDCA prophylaxis is not in the FDA label for any GLP-1 — it is established in the bariatric-surgery world but has not been formally trialed in GLP-1 patients.

Stopping a GLP-1 because of an acute gallbladder event is a clinical decision, not a default — see our what happens when you stop semaglutide and how to taper off GLP-1 safely guides for the full discussion. After cholecystectomy, there is no published evidence that resuming a GLP-1 is unsafe; many clinicians do, with the understanding that the absent gallbladder removes one of the two mechanisms entirely.

Related research

• GLP-1 side effects: what the trials actually showed — the broader STEP/SURMOUNT adverse-event picture this article zooms in on.
• GLP-1 side effect questions answered — short-form Q&A on the most-searched GLP-1 safety queries.
• Practical GLP-1 nausea management — distinguishes ordinary GLP-1 GI symptoms from the right-upper-quadrant pain of cholecystitis.
• Does GLP-1 cause liver damage? NAFLD & MASH evidence — companion piece on the hepatic side of the hepatobiliary system.
• How to taper off a GLP-1 safely — relevant if a gallbladder event prompts a clinician recommendation to stop.
• GLP-1 + surgery and anesthesia (ASA guidance) — directly relevant if cholecystectomy is on the table and the patient is still on a weekly GLP-1.